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and Ning Wang2*Abstract
Background: To estimate the incidence and risk factors for mortality in HIV-1-infected patients in China.
Methods: Information on AIDS-related deaths was collected from the Chinese Center for Disease Control and
Prevention’s Disease Surveillance Information Reporting System and AIDS Prevention and Control Information System.
Results: A total of 379,348 HIV cases were recorded in the databases from 2006. Among those, 138,288 patients
were reported as having developed AIDS and 72,616 (19%) died of AIDS after data was extracted from the
databases in January 2011. Mortality was higher among those patients aged 50 years old or older (AOR: 3.41, CI:
1.47-7.91) who had been infected by intravenous drug use (AOR: 1.65, CI: 1.28-2.14) or blood transfusion/donation
(AOR: 2.18: 1.18-3.99). Compared to patients who had not initiated highly active antiretroviral therapy (HAART),
those who had initiated HAART were more likely to have a long interval of time between infection confirmation
and AIDS-related death.
Conclusions: The effective reduction of AIDS mortality could be improved through timely treatment.
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There are currently an estimated 780,000 people living with
HIV in China; at the end of 2011, the cumulative number
of reported deaths since the beginning of the HIV epidemic
was 93,000 [1]. A report released by the Ministry of Health
in 2009 showed that HIV/AIDS had become the leading
cause of death from infectious disease in China [2].
The expansion of highly active antiretroviral therapy
(HAART) in recent years has offered a hope of preventing
thousands of deaths [3-12]. HAART [13] use has notably
reduced HIV-related morbidity and mortality in both in-
dustrialized and low-income settings since 1996 [4,14-17].
HAART has also contributed additional benefits such as
prolonged disease-free survival, durable HIV virologic
suppression, immunologic (CD4 cell) repletion, and* Correspondence: zhihangpeng@njmu.edu.cn; wangnbj@163.com
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unless otherwise stated.reductions in hospitalization rates [14,18,19]. As a result
of the Chinese government scaling up the National Free
Antiretroviral Treatment Programme (NFATP) in 2003,
approximately 10,000 people in China were receiving
HAART by the end of 2011 [20].
Most previous reports in China have focused on the
effects of HAART on clinical and immunologic outcomes
compared to those observed in resource-rich settings [21].
Previous studies have already identified that patients
starting HAART with low CD4 cell counts have fewer
opportunistic infections such as tuberculosis, acute sepsis,
cryptococcosis, and toxoplasmosis [22-25]. However,
in-depth analysis and systematic research into causes of
death among people with HIV/AIDS in China is lacking.
This study presents data from the China Disease Pre-
vention and Control Information System on changes in
AIDS mortality through December 31, 2010. It also deter-
mines the incidence and related risk factors of mortality
following the widespread availability of HAART in China
after 2003.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Data collection
Data on HIV/AIDS patients were collected from the
China Disease Prevention and Control Information
System. For mortality cases, detailed information was
downloaded from the Disease Surveillance Information
Reporting System and AIDS Prevention and Control In-
formation System. These databases contain information
on patient demographic characteristics, reported prov-
inces of residence, survival time (from diagnosis to
death), cause of death, and HAART use. If one case was
contained in both databases, we selected the informa-
tion on the case from AIDS Prevention and Control
Information System. All data were assessed from January
1, 2006 to December 31, 2010. HAART was scaled up
nationwide in 2003, with data prospectively included in
the database after 2004. However, the data collected
from 2004 to 2005 covered only part of the provinces,
and nationwide collection was not yet initiated; for this
reason, the mortality data did not start until 2006.
All records in the databases had undergone quality
control, and cases were confirmed in a laboratory. Data
were recorded solely for individuals from mainland
China, excluding people from Hong Kong, Macao and
Taiwan. Non-Chinese citizens were also excluded from
our study.
A second analysis was conducted on mortality cases
from January 1, 2011 to July 31, 2011. The effects of
treatment on death were analyzed by studying the num-
ber of days between the date of death and the date of
either the first CD4 test or the date of AIDS diagnosis if
CD4 test results were unavailable.Ethics statement
This study, including design, recruitment, consent, and
assessment procedures, was reviewed and approved by the
Institutional Review Board of Nanjing Medical University.Cause of death
Causes of death for cases reported in the Data Informa-
tion Management System were verified. Among the
32,562 cases with a cause of death listed as “other rea-
sons”, some were confirmed as AIDS-related death by
verifying the information filed. When the cause of death
was listed as tuberculosis, opportunistic infections (OI),
pneumocystis pneumonia (PCP), or AIDS-related dis-
ease, the cause of death was reclassified as AIDS. Taking
into account that tuberculosis is prevalent in China,
those deaths were removed from the analysis of AIDS-
related deaths if the patient’s last CD4 did not fall below
200/uL, to avoid overestimating the number of AIDS-
related deaths.Identify key variables
A late diagnosis of AIDS-related death was defined as a
diagnosis of AIDS (CD4 < 200 cells/μL or AIDS-related
clinical symptoms) [26] where death occurred within
one year after an HIV diagnosis. All patients were
eligible for free treatment if their HIV was in WHO
clinical stage 3 or 4, or if they had a CD4 count < 200
cells/μL or <350 cells/μL after 2008. Untreated deaths
were defined as patients who died without initiating
treatment. Mortality cases with antiviral treatment
information in the treatment database were matched to
the same cases in the mortality database. The deaths of
patients who were not listed in the treatment registry
were considered untreated deaths.
Statistical analysis
SPSS (version 20.0), Stata (version 12.0) and Excel (version
2010) were used for data analysis. Descriptive analyses
were conducted to describe mortality cases’ characteris-
tics, including mean (±SD), median (interquartile range,
IQR), and frequencies (%). A logistic regression was ap-
plied to determine the risk factors of HIV/AIDS mortality.
Kaplan-Meier survival curves were used to estimate the
probability of death and the median time to death after
HAART initiation. The log-rank test was used to compare
the median time to death between the four groups. Statis-
tical significance was assessed at the 0.05 level, and all
hypothesis tests were two-sided.
Results
General characteristics
In our study, annual reported deaths from HIV/AIDS
from 2006 to 2010 comprised 1809; 5544; 9748; 12,287;
and 18,987 cases, respectively. The estimated annual num-
ber of new infections was 70,000; 50,000; 48,000; and
48,000 in 2005, 2007, 2009, and 2011, respectively. Based
on our data, we estimated the annual mortality rates as
being 2.5% in 2007, 3.5% in 2008 and 5.0% in 2010. The
actual annual number of HIV/AIDS deaths after verifying
cause of death from 2006 to 2010 was 7,013; 9,298;
11,921; 13,832; and 13,981, respectively, revealing a slower
increase than in the data reported. Annual cases of AIDS-
related deaths among actual annual cases from 2006 to
2010 were 2764; 3575; 4877; and 5675; and 5,793, respect-
ively, showing a relatively slight upward trend.
The total number of deaths in male patients was 54,904.
Among all patients, death was more common among those
who were 20–49 years of age (75.3%). The median age of
death was 38.5 years old, 38.4 years for males and 38.7 years
for females. Among self-reported sources of transmission,
the proportions of total deaths from infections through
heterosexual transmission, injection drug use (IDU), blood
transfusion/donation, homosexual transmission and others
were 31.7%, 28.4%, 24.0%, 0.8% and 1.1%, respectively.
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tive deaths reported the use of HAART (Table 1).
The three risk factors most strongly related to mortality
were age, not having received HAART and having mul-
tiple transmission routes. IDUs (AOR, adjusted odds ratio:
1.65, CI, confidence interval: 1.28-2.14) and blood transfu-
sion/donations (AOR: 2.18, CI: 1.18-3.99) were signifi-
cantly more likely to having a high mortality compared to
those infected through heterosexual transmission; how-
ever, the statistical results of individuals infected by homo-
sexual transmission (AOR: 0.33, CI: 0.23-0.47) were just
the opposite. Patients aged 50 years old or older (AOR:
3.41, CI: 1.47-7.91) and those who had not received
HAART were also significantly likely to have a high
mortality. Although sex and marital status were not
significantly associated with mortality, female gender and
a status of married or divorced had a high risk of mortality
in the unadjusted analysis, but these factors were not
included in the adjusted analysis (Table 1).
AIDS deaths were reported in the 31 mainland prov-
inces by the end of 2010. The top six provinces with the
highest cumulative number of reported HIV/AIDS cases,
as well as the highest cumulative number of reported
deaths, were Yunnan, Guangxi, Henan, Sichuan, XinjiangTable 1 Demographics of the actual HIV/AIDS deaths and the
Year 2006 2007 2008 2009
Death 7013 9298 11921 13832
Sex
Male 5167 6974 9013 10688
Female 1846 2324 2908 3144
Age (median) 37 38 39 40
0-20 170 226 210 231
20-29 1199 1455 1632 1667
30-39 2817 3690 4526 4870
40-49 1582 2028 2755 3195
>50 1244 1899 2798 3869
Transmission routes
Heterosexual 1423 2509 4264 5974
IDU 1872 2729 3402 3784
Blood transfusion/donation 2288 2178 2154 1513
Homosexual 22 48 96 151
Others 94 133 113 146
Marital status
Unmarried 1386 1997 2479 2843
Married 4260 5395 7093 8071
Divorced or widowed 743 1171 1536 2128
Received HAART
No 5380 7423 8945 10856
Yes 1633 1875 2513 2976and Guangdong. The top five provinces with the highest
proportion of cumulative reported deaths accounting for
the cumulative number of reported HIV/AIDS cases were
Shanxi, Hubei, Henan, Hebei, and Anhui. The proportion
of HIV/AIDS-related deaths was low in provinces such as
Beijing, Shanghai, Tianjin, and Zhejiang (Table 2).
Characteristics according to time since HIV diagnosis and
HAART
Among the 72,616 deaths, the median time between diag-
nosis and death was 0.7 years (IQR: 0.1, 2.6). The median
time of HIV infection between diagnosis and death was
0.9 years (IQR: 0.1, 2.9). Simultaneously, the median time
of AIDS infection between diagnosis and death was 0.6 years
(IQR: 0.1, 2.4).
The median time between diagnosis and death for
patients receiving treatment was 1.6 years (IQR: 0.44,
3.62), while the median time between diagnosis and
death for untreated patients was 0.5 years (IQR: 0.1, 2.2).
Table 3 presents and compares the interval between
diagnosis and death according to HAART initiation status.
The different day ranges between diagnosis and death
have different numbers of death, more than 180 days was
the most, less than 30 days, 30 to 60 days, 60 to 90 days,ir associated risk factors from 2006 to 2010
2010 Total No. (%) OR (95% CI) AOR (95% CI)
13981 72616
10874 54904 (75.6) 1.0 1.0
3107 17712 (24.4) 1.51 (1.22-1.87) 1.02 (0.79-1.32)
41 38.5 1.05 (1.04-1.06) 1.03 (1.01-1.06)
214 1624 (2.3) 1.0 1.0
1589 11153 (15.4) 0.85 (0.41-1.78) 0.89 (0.40-1.97)
4597 27183 (37.4) 1.66 (0.81-3.41) 1.34 (0.61-3.00)
3466 16365 (22.5) 2.02 (0.97-4.21) 1.39 (0.61-3.19)
4115 16188 (22.3) 5.33 (2.55-11.15) 3.41 (1.47-7.91)
6796 23009 (31.7) 1.0 1.0
3942 20616 (28.4) 1.36 (1.11-1.68) 1.65 (1.28-2.14)
1495 17487 (24.0) 3.34 (1.98-5.61) 2.18 (1.18-3.99)
275 615 (0.8) 0.18 (0.14-0.25) 0.33 (0.23-0.47)
127 792 (1.1) 0.77 (0.50-1.20) 0.87 (0.48-1.56)
2935 14547 (20.0) 1.0 1.0
7938 42239 (58.2) 2.43 (1.99-2.97) 1.16 (0.89-1.50)
2378 9109 (12.5) 2.53 (1.95-3.28) 1.12 (0.81-1.56)
10866 58318 (80.3) 1.0 1.0
3115 14298 (19.7) 0.41 (0.32-0.51) 0.11 (0.08-0.14)
Table 2 The provincial statistics of the cumulative reported cases and the cumulative AIDS-related death cases
with HAART
Province Cumulative reported cases Cumulative death cases Proportion of
deaths (%)Number Accepted HARRT Percentage (%) Number Accepted HARRT Percentage (%)
Anhui 6590 3564 54.1 1730 446 25.8 26.3
Beijing 5259 1053 20 148 25 16.9 2.8
Fujian 2649 710 26.8 568 55 9.7 21.4
Gansu 893 234 26.2 163 19 11.7 18.3
Guangxi 63127 16560 26.2 1359 1329 9.8 21.5
Guangdong 28534 4471 15.7 5829 437 7.5 20.4
Guizhou 10290 1351 13.1 1826 143 7.8 17.7
Hainan 975 98 10.1 292 9 3.1 29.9
Hebei 1913 754 39.4 607 110 18.1 31.7
Henan 49325 32282 65.4 1467 7471 50.9 29.7
Heilongjiang 1571 412 26.2 228 34 14.9 14.5
Hubei 6613 2689 40.7 2039 439 21.5 30.8
Hunan 10794 2736 25.3 2831 374 13.2 26.2
Jilin 1504 479 31.8 387 66 17.1 25.7
Jiangsu 4084 1337 32.7 643 102 15.9 15.7
Jiangxi 2556 983 38.5 822 169 20.6 32.2
Liaoning 2785 585 21 347 49 14.1 12.5
Neimengu 621 119 19.2 97 20 20.6 15.6
Ningxia 370 77 20.8 44 10 22.7 11.9
Qinghai 317 98 30.9 45 11 24.4 14.2
Shandong 2272 754 33.2 547 87 15.9 24.1
Shanxi 3055 1180 38.6 1002 158 15.8 32.8
Shanxi 1569 460 29.3 309 72 23.3 19.7
Shanghai 5260 1154 21.9 239 48 20.1 4.5
Sichuan 38356 5041 13.1 5485 440 8 14.3
Tianjin 885 237 26.8 99 22 22.2 11.2
Tibet 126 8 6.3 10 1 10 7.9
Xinjiang 33519 4119 12.3 4107 379 9.2 12.3
Yunnan 79433 18953 23.9 1222 1537 12.6 15.4
Zhejiang 4713 1695 36 494 88 17.8 10.5
Chongqing 9390 1603 17.1 1179 148 12.6 12.6
Nationwide 379348 105796 27.9 72616 14298 19.7 19.1
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Among all deaths by the end of 2010, 80.3% (58318/
72616) of patients who died did not receive HAART and
75.0% (43732/58318) of those had no CD4 test result. For
those patients with CD4 test results, 62.8% (9167/14586)
had a CD4 count below 200 at their first lab test, and
78.9% (11643/14586) had a CD4 count below 350 at their
first lab test. Compared to patients who had not initiated
HAART, those who had initiated HAART were more
likely to have a long interval of time between diagnosis
and death (χ2 = 3621.19, p < 0.001).According to the AIDS Network Reporting System, by
the end of 2010, 56.1% (40746/72616) of the cumulative
number of patients who died were late diagnoses. Of those
who died after receiving a late diagnosis, 73.5% were male,
64.6% were married, and 74.5% were ethnically Han.
Transmission categories for these deaths included hetero-
sexual transmission (43.4%), IDU (15.9%), blood donation
(14.4%), and blood transfusion (8.3%). Most (61.9%) pa-
tients were first diagnosed in their counties of residence.
Among the patients who died who had never initiated
HAART, 77.4% were male, 55.5% were married, and
Table 3 HAART and CD4 test results of the cumulative HIV/AIDS deaths by the end of 2010
The interval between infection




First laboratory CD4 count No CD4 test result
No. (%)≤200 200-350 >350 Total No. (%)
<30 15615 610 (3.9) 1346 77 61 1484 (9.5) 13521 (86.6)
30- 5543 788 (14.2) 1014 77 54 1145 (20.7) 3610 (65.1)
60- 4002 832 (20.8) 831 52 60 943 (23.6) 2227 (55.6)
90- 7164 1573 (22.0) 1400 161 170 1731 (24.2) 3860 (53.9)
≥180 40292 10495 (26.0) 4576 2109 2598 9283 (23.0) 20514 (50.9)
Total 72616 14298 (19.7) 9167 2476 2943 14586 (20.0) 43732 (60.2)
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cluded heterosexual transmission (33.2%), IDU (32.0%),
blood donation (11.3%) and blood transfusion (5.4%).
Most (60.9%) patients were first diagnosed in their
counties of residence (Table 4).
Underlying cause of death
Out of 72,616 total deaths, there were 63,785 cases with
information on cause of death, of which 31,223 (49.0%)
were considered AIDS-related deaths and 32,562 had
other causes of death. AIDS deaths accounted for 57.1%
of all deaths after cause of death was verified. Results
are shown in Table 5.
Characteristics of treated deaths by baseline CD4 cell
counts
Based on the data collected from January 1, 2011 to July
31, 2011, most of the patients who died without initiating
HAART died either more than 12 months from diagnosis
(n = 2,027) or less than three months from diagnosis
(n = 2,543). More than half (57.5%) never received a CD4
test before their death. Among the 2,375 patients who had
received a CD4 test, 1,772 had first CD4 test results that
met the criteria to initiate treatment. Among 603 patients
with CD4 counts >350 cells/μL, 210 (34.8%) had a subse-
quent CD4 test with a count < 350 cells/μL (Table 6).
The probability of survival after receiving HAART is
shown by the Kaplan-Meier method in Figure 1. The study
population was analyzed in four groups based on baseline
CD4 cell counts (Group 1: CD4 count <50 cells/μL, Group
2: CD4 count ≥50 cells/μL and ≤200 cells/μL, Group 3:
CD4 count >200 cells/μL and ≤350 cells/μL, and Group 4:
CD4 count > 350 cells/μL). Survival rates at 12, 36, and
60 days were 82.1%, 75.9%, and 70.9% in Group 1; 92.6%,
85.8%, and 82.7% in Group 2; 95.9%, 89.6% and 85.6% in
Group 3; and 96.4%, 90.8% and 87.4% in Group 4 (log-rank
test, p <0.001).
Discussion
This study showed some notable findings on causes
of death among a large and demographically diversepopulation of HIV patients. Mortality was higher among
those patients aged 50 years old or older who had been
infected by IDU or blood transfusion/donation and had
not accepted HAART.
According to our study, the risk factor strongly related
to death was age, especially for individuals aged 50 years
old or older. There may be many reasons for this. First
of all, a substantial proportion of elderly people who
meet treatment criteria may give up treatment voluntar-
ily. This is likely to be associated with the personal char-
acteristics of this group, such as having low levels of
education and desiring to reduce the burden on family.
Furthermore, individuals in older age groups may be
likely to refuse treatment as a result of the stigma associ-
ated with HIV/AIDS [27], without the support of social
and family members. Last but not least, elderly people
may be underserved by the public health system, espe-
cially in some less developed areas.
The study noted a significant risk of mortality in indi-
viduals who were infected by IDU and blood transfu-
sion/donation compared to heterosexual transmission.
IDU was the primary mean of transmission at the begin-
ning of China’s HIV epidemic [28], which led to a long
period of infection and late treatment initiation. Conse-
quently, those infected by IDU had a higher mortality
rate, which is consistent with other reports [29,30]. In
addition, the high mortality in IDUs may be associated
with personal characteristics; some foreign studies indi-
cated that the majority of accidental deaths among IDUs
are from drug overdoses [31,32].
Similarly, blood transfusion was also one of the main
routes in the early phase of China [33], most former
plasma donors (FPD) or blood receptors infected by
HIV long time ago, which made the disease developed
long enough to become a danger for bodies and thus a
risk factor for higher mortality [34].
Significantly, there is a protective influence in individ-
uals infected by homosexual transmission, in contrast
with individuals infected by heterosexual transmission.
There may be a bias here due to the database’s small
sample of men who have sex with men (MSM), although
Table 4 Demographics of late diagnosis of HIV deaths





No. (%) No. (%)
Sex
Male 29954 (73.5) 45162 (77.4)
Female 10792 (26.5) 13155 (22.6)
Age (years)
0-9 1062 (2.6) 634 (1.1)
10-19 / 533 (0.9)
20-29 5556 (13.6) 6339 (10.9)
30-39 13709 (33.7) 13795 (23.7)
40-49 9360 (23.0) 8801 (15.1)
50 10981 (27.0) 10567 (18.1)
Marital status
Married 26336 (64.6) 32390 (55.5)
Unmarried 7019 (17.2) 12518 (21.5)
Divorced or widowed 5222 (12.8) 6913 (11.9)
Ethnicity
Han 30373 (74.5) 39220 (67.3)
Zhuang/Wei/Yi/Dai 5352 (13.1) 10078 (17.3)
Other ethnicity / /
Infection Routes
Heterosexual 17693 (43.4) 19387 (33.2)
IDU 6462 (15.9) 18666 (32.0)
Blood Donation 5847 (14.4) 6606 (11.3)
Blood Transfusion 3391 (8.3) 3158 (5.4)
MTCT 510 (1.3) 677 (1.2)
MSM 453 (1.1) 487 (0.8)
Sex (both MSM and heterosexual
) + IDU
283 (0.7) 452 (0.8)
Unknown / 8371 (14.4)
Location of death
Local county 25309 (61.9) 35523 (60.9)
Local city and other county 8116 (19.9) 10671 (18.3)
Local province and other city 5507 (13.5) 9258 (15.9)
Other province 1914 (4.7) 2865 (4.9)
Reporting units
Disease control system 24833 (61.0) 39862 (68.4)
Medical institution 15744 (38.6) 17746 (30.4)
Blood center 26 (0.1) 105 (0.2)
Drug addiction treatment facility 53 (0.1) 472 (0.8)
Table 4 Demographics of late diagnosis of HIV deaths
and untreated deaths by the end of 2010 (Continued)
Occupation
Farmer 24411 (59.9) 31839 (54.6)
Housekeeper and unemployed 4556 (11.2) 9039 (15.5)
Laborer 2083 (5.1) 2784 (4.8)
Retired 1392 (3.4) 1528 (2.6)
Migrant worker 1308 (3.2) 1522 (2.6)
Business / 1346 (2.3)
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years in China [35,36]. Another potential reason may be
that the majority of MSM are relatively young.
The results of our study reveal a statistically significant
difference between accepting HAART or not. The re-
sults provide evidence that increasing HAART coverage
at the population level can decrease HIV-related mortal-
ity, which conforms with the results of overseas findings
such as those from the mid-to-late 1990s in the USA [4],
Europe [37] and in other earlier studies [38-40].
In the five provinces with the highest proportion of
cumulative AIDS deaths, patients who died almost al-
ways had a history of paid blood donation. These regions
excelled at early detection, management of cases and
follow-ups, and reporting deaths. Conversely, in Beijing,
Shanghai, Tianjin, and Zhejiang, the proportion of cu-
mulative AIDS deaths was the lowest among all prov-
inces. The reason for the low AIDS deaths in these areas
may be due to their large migrant populations, whose
high mobility complicates follow-up.
According to previous studies, end-stage patients with
low CD4 counts achieve significantly fewer life-prolonging
effects through HAART than those with high CD4 counts.
However, according to the results of this study, most of
those who died before initiating HAART never had a CD4
test. Efforts should be made to improve coverage of HIV
diagnostic tests and the frequency of CD4 testing in order
to offer timely HAART to prolong survival time. The me-
dian time between diagnosis and death was only 0.7 years,
and nearly half of cases were discovered late. Though
HAART can effectively reduce the fatality rate of HIV/
AIDS, many at-risk individuals do not seek out standard
HIV counseling and testing services. The stigmas associ-
ated with drug use and HIV/AIDS and the fear of arrestTable 5 Cause of death for HIV cases by the end of 2010
Causes of
death
Original report After adjustment
Number of cases % Number of cases %
AIDS 31223 49.0 36438 57.1
Other 32562 51.1 27347 42.9
Total 63785 100.0 63785 100.0
Table 6 CD4 test results for mortality cases from January 1, 2011 to July 31, 2011




Proportion with at least one CD4 test
N (%)
First CD4 test results
<50 50-200 201-350 >350
0-2 2543 567 (22.3%) 360 145 28 34
3-5 457 245 (53.6%) 124 83 18 20
6-8 334 189 (56.6%) 82 62 15 30
9-11 222 120 (54.1%) 33 47 11 29
≥12 2027 1254 (61.9%) 173 274 317 490
Total 5583 2375 (42.5%) 772 611 389 603
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HIV voluntary counseling and testing (VCT) services [41].
It is critical to scale up early monitoring to provide
prompt treatment and effectively reduce AIDS mortality.
The results of this survival analysis indicate the bene-
fits of HAART in reducing overall mortality and AIDS-
related morbidity, which is similar to results in other
studies [42,43]. However, the cumulative number of
HIV-positive adults using HAART in China was less
than 20% by the end of 2010 [20]. The results indicate
that HIV-positive individuals need to be diagnosed much
earlier, which would suggest that HIV testing programs
should be expanded.
In our study, survival analysis in HIV patients received
HAART also indicated that individuals were more likely
to have a long interval of time between diagnosis and
death compared to individuals who had high baseline
CD4 cell counts. The differences were more visible be-
tween Group 1 and Group 4. Timely HAART should be
provided to prolong survival time, as receiving HAART
is the best way to reduce mortality. Mechanisms should
be in place to prevent the development of drug resist-
ance and to enhance clinical services, including imple-
menting viral load testing, increasing adherence, andFigure 1 The survival probability for cases receiving
antiretroviral therapy, arranged by baseline CD4 cell count.providing prompt second-line therapy for patients with
first-line treatment failure.
This study had several limitations. First, data were
used from sentinel detection databases and may not be
representative of all deaths in China, may exclude those
who were homeless or living alone when they died and
may underestimate AIDS-related mortality. Second,
many could have died of AIDS, but if they were never
diagnosed the cause of death could have been listed as
something else and they would not be included in the
databases. Third, data may have been missing from the
databases for other reasons. Missing data may influence
the determination of receiving HAART or not, which
likely underestimates the proportion of patients who
had initiated HAART.
Conclusions
In summary, early diagnosis of HIV can maximize the ef-
fectiveness of HAART. It is essential to continue moni-
toring HAART uptake and adherence in China, which
will help to save lives.
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